WA’s Linear Clinical Research at Heart of the Fight Against COVID-19
The ECA is excited to hear news from WA, that Perth-based company, Linear Clinical Research, has been selected to undertake a trial of one of the first vaccines in the world to demonstrate safety and immune response against COVID-19.
Linear are both a WA and Australian Export Awards winner for their outstanding achievements in Health and Biotechnology.
“WA is in the unique position of working towards successfully suppressing the disease, so medical experts can dedicate resources to prevention. We are fortunate to be one of the few countries in the world to still be offering functional clinical trial facilities because we do not have large volumes of COVID-19 cases as compared to other parts of the world.”
Mr Rogers noted Linear was awarded the study because of their extensive experience testing the world’s latest medical breakthroughs combined with its industry leading digital innovations.
There are more than 60 candidate COVID-19 vaccines in development around the world, but only a few are entering early clinical trials in human volunteers.
Linear will conduct a human trial of the ground-breaking vaccine candidate which is being developed to help the body produce antibodies to fight the deadly coronavirus which causes COVID-19 disease.
The vaccine candidate, COVID-19 S-Trimer, has been developed by China-based, global clinical-stage biotechnology company Clover Biopharmaceuticals.
The Phase 1 clinical trial of the COVID-19 S-Trimer vaccine is planned to involve healthy adult and healthy elderly trial participants. Linear will be seeking volunteers to participate in the study within the next 2 months.
If successful, a larger Phase 2b/3 clinical trial involving thousands of people around the world would be conducted immediately, and it is hoped that the COVID-19 vaccine will be widely available upon confirmation of its safety and efficacy.
Read more about Linear and the study at https://www.linear.org.au/